Özet:

In China, the new type of coronavirus (SARS-CoV2), which began to be seen in December 2019, has rapidly spread throughout the world and has become a global problem. COVID-19 is more common in people with cardiovascular disease, hypertension, diabetes, and more severe. It should be discussed whether rheumatoid diseases and medications used in their treatment increase the risk of developing COVID-19. There is a lack of data on the development of COVID-19 in literature, especially in patients with ankylosan spondylitis. While we use Anti-TNF in this presentation of the fact, we intended to provide two Ankylosan Spondylitis, who suffered COVID-19 infection. Our young patient with no comorbidity quickly healed with antiviral and support treatment. Our elderly patient with chronic cardiovascular and kidney disease was more severe and resulted in a loss of life. The course and mortality of the COVID-19 infection are closely related to the underlying comorbid diseases. Through ankylosan spondylitis two examples of phenomena, we aimed at discussing the effect of rheumatoid diseases and immunosuppressive treatments used on the path of new type of coronavirus infection, accompanied by literature.